- Home
- AMRN
as 11-15-2024 4:00pm EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
| Founded: | 1989 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 236.4M | IPO Year: | 1993 |
| Target Price: | N/A | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $1.37 | Next Earning Date: | 10-30-2024 |
| Revenue: | $241,021,000 | Revenue Growth: | -25.25% |
| Revenue Growth (this year): | -31.32% | Revenue Growth (next year): | -13.24% |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
GuruFocus.com
17 days ago
Amarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ...
Zacks
17 days ago
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
Motley Fool
18 days ago
Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript
Associated Press Finance
18 days ago
Amarin: Q3 Earnings Snapshot
GlobeNewswire
18 days ago
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
GuruFocus.com
19 days ago
Amarin Corp PLC (AMRN) Q3 2024 Earnings Report Preview: What To Look For
GuruFocus.com
a month ago
Amarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.